The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 10, 2023

Filed:

Aug. 04, 2022
Applicant:

Scipher Medicine Corporation, Waltham, MA (US);

Inventors:

Susan Ghiassian, Boston, MA (US);

Theodore R. Mellors, Boston, MA (US);

Marc Santolini, Waltham, MA (US);

Asher Ameli, Waltham, MA (US);

Nancy Schoenbrunner, Charlestown, MA (US);

Viatcheslav R. Akmaev, Sudbury, MA (US);

Keith J. Johnson, Wayland, MA (US);

Assignee:

SCIPHER MEDICINE CORPORATION, Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 37/06 (2006.01); C07K 16/24 (2006.01); G16B 20/20 (2019.01); G16H 10/60 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01); G16H 20/10 (2018.01); A61P 19/02 (2006.01); G16B 40/00 (2019.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
G16B 20/20 (2019.02); A61K 38/1793 (2013.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 16/241 (2013.01); G16B 40/00 (2019.02); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01);
Abstract

Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.


Find Patent Forward Citations

Loading…